BACKGROUND
Lennox-Gastaut syndrome (LGS) is a severe, drug-resistant developmental and epileptic encephalopathy for which corpus callosotomy (CC) can be a particularly effective option for seizure control. However, this benefit must be weighed against the tradeoff of permanent corpus callosum disconnection. Although us...
Debopam Samanta, P. Ramani, Taylor J. Abel et al.· Epilepsy Research· 0 citations
INTRODUCTION
Epilepsy with myoclonic-atonic seizures (EMAtS), historically termed Doose syndrome, is a developmental and epileptic encephalopathy characterized by the usually abrupt onset of multiple generalized seizure types, including myoclonic-atonic seizures, in early childhood. Advances in genetic diagnostics, ant...
Debopam Samanta· Expert Review of Neurotherap...· 0 citations
Because of persistent seizures despite antiseizure medications, glycerol phenylbutyrate (GPB), a prodrug of 4-PBA, was initiated, resulting in complete seizure freedom and reduction of epileptiform discharges on follow-up electroencephalography.
O. El Ghawi, Eniya Beemarajan, Debopam Samanta et al.· Journal of Child Neurology· 0 citations
Evaluating the management practices of Infantile Epileptic Spasms Syndrome across tertiary pediatric hospitals in the United States found areas of consensus (use of overnight video EEG at initial diagnosis, use of high‐dose prednisolone as initial treatment, preference for sequential as opposed to combination therapy,...
Akshat Katyayan, Christina Briscoe, Sonam Bhalla et al.· Epilepsia Open· 0 citations
It is found that the association between early epilepsy surgery and seizure reduction in palliative procedures reflects the heterogeneity of the population, including different types of surgical procedures and lesional and nonlesional epilepsies.
Robert M Crutcher, David E. Horvat, A. Caraway et al.· Epilepsia· 0 citations
EIMFS remains one of the most refractory epilepsy syndromes of infancy and international collaborative registries, standardized outcome measures, genotype-stratified biomarker studies, and rapid point-of-care genomic testing are urgently needed to advance evidence-based care.
Critical unmet needs include earlier molecular diagnosis, precision therapies targeting developmental outcomes beyond seizure control, and prospective international registries to characterize the long-term natural history of EIDEE.
Debopam Samanta· Brain & development (Tokyo....· 0 citations
Similar children evaluated at different institutions had significant differences in the odds of not being recommended surgery, suggesting that institutional decision-making contributes importantly to surgical candidacy.
A. Caraway, Nancy A. Mcnamara, Andrew T. Knox et al.· Epilepsia· 0 citations
Delays from DRE diagnosis were independently associated with reduced seizure freedom, supporting presurgical evaluation within 1 year as an evidence-based quality benchmark, and DRE-to-evaluation interval, not total epilepsy duration, predicted outcomes.
Debopam Samanta, A. Caraway, Andrew T. Knox et al.· Neurology Clinical Practice· 0 citations
A comprehensive narrative review of studies indexed in PubMed/MEDLINE, Embase, Cochrane Library, ClinicalTrials.gov, and American Epilepsy Society proceedings through January 2026 positions STXBP1-RD as a leading test case for precision medicine in DEEs.
A rapidly advancing precision-therapy pipeline-including antisense oligonucleotides to upregulate the intact allele, AAV-based gene replacement, CRISPR-mediated transcriptional activation, epigenetic modulators, and rational pathway-targeted small molecules-offers realistic prospects for disease modification.
Debopam Samanta· Epilepsy & Behavior· 2 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
